Chemed
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Chemed's revenues will increase 3.9% and EPS will expand 5.6%.
The average estimate for revenue is $368.1 million. On the bottom line, the average EPS estimate is $1.33.
Revenue details
Last quarter, Chemed logged revenue of $366.6 million. GAAP reported sales were 3.9% higher than the prior-year quarter's $352.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $1.38. GAAP EPS of $1.17 for Q1 were 10% higher than the prior-year quarter's $1.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 27.9%, 80 basis points better than the prior-year quarter. Operating margin was 10.6%, 70 basis points better than the prior-year quarter. Net margin was 6.1%, 30 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $1.49 billion. The average EPS estimate is $5.66.
Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 102 members out of 140 rating the stock outperform, and 38 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Chemed a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $82.00.
Is Chemed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Chemed to My Watchlist.
